Investment Trusts

BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)46.25
  • Today's Change-0.300 / -0.64%
  • Shares traded42.41k
  • 1 Year change+16.50%
  • Beta0.9294
Data delayed at least 15 minutes, as of Feb 09 2026 16:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

On Monday, BB Biotech AG (BION:SWX) closed at 46.25, -6.85% below its 52-week high of 49.65, set on Jan 23, 2026.
52-week range
Today
24.35Apr 07 202549.65Jan 23 2026
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding55.40m
Market cap2.56bn CHF
Total assets2.76bn CHF
Total expense ratio--
High46.75
Low45.80
Previous close46.55
Average volume88.06k
YTD Change+2.89%
Beta0.9294
Diluted NAV (est)51.25
Diluted NAV (last pub)49.85
Premium/Discount--
Net Gearing0.00%
Annual div (ADY)2.25
CHF
Annual div yield (ADY)4.83%
Div ex-dateMar 21 2025
Div pay-dateMar 25 2025
Next div ex-dateMar 23 2026
Next div pay-dateMar 25 2026
Data delayed at least 15 minutes, as of Feb 09 2026 16:31 GMT.
More ▼

Board of Directors

1/4

Dr. Erich Hunziker, Chairman

2/4

Dr. Clive Meanwell, Vice Chairman

3/4

Prof. Dr. Dr. Klaus Strein, Member

4/4

Dr. Thomas von Planta, Member

Contact

BB Biotech AG
Schwertstrasse 6
8200 Schaffhausen/Switzerland

T: +41 52 624 08 45
E: info(at)bbbiotech.com
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.